Sierra Ocean LLC Makes New $40,000 Investment in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Sierra Ocean LLC bought a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 76 shares of the medical equipment provider’s stock, valued at approximately $40,000.

Several other large investors also recently modified their holdings of ISRG. Berbice Capital Management LLC bought a new stake in shares of Intuitive Surgical in the fourth quarter worth $26,000. Godsey & Gibb Inc. grew its holdings in Intuitive Surgical by 140.0% during the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 35 shares during the period. MidAtlantic Capital Management Inc. bought a new stake in Intuitive Surgical during the third quarter valued at about $33,000. Decker Retirement Planning Inc. bought a new stake in Intuitive Surgical during the fourth quarter valued at about $36,000. Finally, Capital Performance Advisors LLP bought a new stake in Intuitive Surgical during the third quarter valued at about $38,000. Institutional investors own 83.64% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Jamie Samath sold 94 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $571.11, for a total transaction of $53,684.34. Following the transaction, the chief financial officer now owns 2,630 shares of the company’s stock, valued at approximately $1,502,019.30. This represents a 3.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Amal M. Johnson sold 4,635 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total value of $2,626,191.00. Following the transaction, the director now directly owns 12,275 shares in the company, valued at approximately $6,955,015. This represents a 27.41 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,348 shares of company stock valued at $3,587,582 over the last ninety days. 0.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ISRG has been the topic of several research analyst reports. Royal Bank of Canada boosted their price objective on Intuitive Surgical from $611.00 to $641.00 in a research report on Monday, January 27th. Morgan Stanley upgraded Intuitive Surgical from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $522.00 to $650.00 in a research report on Monday, December 2nd. Leerink Partners boosted their price objective on Intuitive Surgical from $490.00 to $548.00 in a research report on Monday, January 27th. UBS Group boosted their price objective on Intuitive Surgical from $500.00 to $560.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Finally, Barclays boosted their price objective on Intuitive Surgical from $610.00 to $674.00 in a research report on Monday, January 27th. One analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus price target of $613.10.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG opened at $595.55 on Tuesday. The business’s 50 day moving average is $559.48 and its two-hundred day moving average is $520.19. Intuitive Surgical, Inc. has a 1-year low of $364.17 and a 1-year high of $616.00. The stock has a market capitalization of $212.12 billion, a P/E ratio of 92.91, a PEG ratio of 5.67 and a beta of 1.39.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.